Change - Announcement of Cessation::Cessation of Chief Product Officer
Issuer & Securities
CLEARBRIDGE HEALTH LIMITED
CLEARBRIDGE HEALTH LIMITED - SG1EB6000000 - 1H3
Change - Announcement of Cessation
Date &Time of Broadcast
Announcement Sub Title
Cessation of Chief Product Officer
Submitted By (Co./ Ind. Name)
Chairman, Non-Executive Non-Independent Director
Description (Please provide a detailed description of the event in the box below)
This announcement has been prepared by Clearbridge Health Limited (the "Company") and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST"). The Sponsor has not independently verified the contents of this announcement.
This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Mr. Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.
Name Of Person
Wu En-Tzu Andrew (Wu Enci Andrew)
Is effective date of cessation known?
If yes, please provide the date
Detailed Reason (s) for cessation
To pursue other interests.
The Sponsor after having interviewed Mr Wu, is satisfied that other than as disclosed in this announcement, there are no material reasons for the resignation of Mr Wu.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
Any other relevant information to be provided to shareholders of the listed issuer?
Date of Appointment to current position
Does the AC have a minimum of 3 members (taking into account this cessation)?
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Product Officer
Role and responsibilities
Responsible for the management of the Group's clinical diagnostics service laboratories, the conduct of business development of new diagnostic technologies and the development of innovative precision medicine diagnostics.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Shareholding interest in the listed issuer and its subsidiaries?
Past (for the last 5 years)
SAM Laboratory Pte. Ltd.